Morrison & Foerster (MoFo) has advised UK biotech company Vernalis on a $400m (£218m) exclusive licensing agreement for North American sales and marketing rights to Endo Pharmaceuticals Holdings.

It is the second-largest US drug licensing deal by a European biotechnology company.